Global Stock News

Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker

Zepbound Price Cuts, GLP‑1 Boom and What Comes Next for the Trillion‑Dollar Drugmaker

Eli Lilly’s stock is trading just below record highs after a historic run driven by obesity and diabetes drugs. Fresh price cuts, powerful earnings and evolving obesity guidelines are reshaping the outlook as of December 2, 2025.


Eli Lilly Stock Today: High Price, High Expectations

As of mid‑day on December 2, 2025, Eli Lilly and Company (NYSE: LLY) is trading around $1,057–$1,060 per share, down roughly 1–2% on the day but still close to its recent record highs. [1]

At this level:

  • Lilly’s market capitalization is just under $1 trillion, after briefly crossing that mark on November 21, becoming the first drugmaker and first healthcare company ever to join the trillion‑dollar club. [2]
  • The stock has climbed about one‑third over…

Source link

Share this article

Scroll to Top